sub:assertion {
d:DB01149 v:identifier "DB01149" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB01149" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB01149> ;
dv:drugbank-id "APRD00402" , "DB01149" ;
dv:x-atc <
http://bio2rdf.org/atc:N06AX06> ;
dv:x-cas <
http://bio2rdf.org/cas:83366-66-9> ;
dv:x-chebi <
http://bio2rdf.org/chebi:7494> ;
dv:x-chemspider <
http://bio2rdf.org/chemspider:4294> ;
dv:x-dpd <
http://bio2rdf.org/dpd:2242822> ;
dv:x-kegg <
http://bio2rdf.org/kegg:C07256> ;
dv:x-ndc <
http://bio2rdf.org/ndc:0087-0031-47> ;
dv:x-pharmgkb <
http://bio2rdf.org/pharmgkb:PA450603> ;
dv:x-pubchemcompound <
http://bio2rdf.org/pubchem.compound:4449> ;
dv:x-pubchemsubstance <
http://bio2rdf.org/pubchem.substance:46508323> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Nefazodone> ;
dct:description "Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia]"@en ;
dct:identifier "drugbank:DB01149" ;
dct:title "Nefazodone"@en ;
a dv:Drug ;
rdfs:label "Nefazodone [drugbank:DB01149]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB01149> , <
http://www.drugs.com/cdi/nefazodone.html> , <
http://www.rxlist.com/cgi/generic/nefaz.htm> .
}